1. Home
  2. VCEL vs KYN Comparison

VCEL vs KYN Comparison

Compare VCEL & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCEL
  • KYN
  • Stock Information
  • Founded
  • VCEL 1989
  • KYN 2004
  • Country
  • VCEL United States
  • KYN United States
  • Employees
  • VCEL N/A
  • KYN N/A
  • Industry
  • VCEL Biotechnology: Biological Products (No Diagnostic Substances)
  • KYN Finance/Investors Services
  • Sector
  • VCEL Health Care
  • KYN Finance
  • Exchange
  • VCEL Nasdaq
  • KYN Nasdaq
  • Market Cap
  • VCEL 2.1B
  • KYN 2.1B
  • IPO Year
  • VCEL 1997
  • KYN N/A
  • Fundamental
  • Price
  • VCEL $34.05
  • KYN $12.26
  • Analyst Decision
  • VCEL Strong Buy
  • KYN
  • Analyst Count
  • VCEL 6
  • KYN 0
  • Target Price
  • VCEL $61.50
  • KYN N/A
  • AVG Volume (30 Days)
  • VCEL 565.9K
  • KYN 561.5K
  • Earning Date
  • VCEL 07-31-2025
  • KYN 01-01-0001
  • Dividend Yield
  • VCEL N/A
  • KYN 8.99%
  • EPS Growth
  • VCEL 2045.40
  • KYN N/A
  • EPS
  • VCEL 0.13
  • KYN 0.71
  • Revenue
  • VCEL $249,119,000.00
  • KYN N/A
  • Revenue This Year
  • VCEL $18.35
  • KYN N/A
  • Revenue Next Year
  • VCEL $22.47
  • KYN N/A
  • P/E Ratio
  • VCEL $256.98
  • KYN $13.79
  • Revenue Growth
  • VCEL 16.13
  • KYN N/A
  • 52 Week Low
  • VCEL $33.09
  • KYN $7.84
  • 52 Week High
  • VCEL $63.00
  • KYN $9.88
  • Technical
  • Relative Strength Index (RSI)
  • VCEL 40.14
  • KYN 46.99
  • Support Level
  • VCEL $33.34
  • KYN $12.14
  • Resistance Level
  • VCEL $36.81
  • KYN $12.67
  • Average True Range (ATR)
  • VCEL 1.36
  • KYN 0.19
  • MACD
  • VCEL -0.13
  • KYN -0.00
  • Stochastic Oscillator
  • VCEL 20.14
  • KYN 37.88

About VCEL Vericel Corporation

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: